Toward Guidelines for RCT Measurements.. What are the characteristics of an acceptable measurement for RCT?
|
|
0
|
1008
|
February 10, 2023
|
What is a fake measurement tool and how are they used in RCT
|
|
46
|
17040
|
January 23, 2023
|
Rescue analysis for % change from baseline as an outcome in RCT
|
|
16
|
2244
|
January 16, 2023
|
The Clinical and Statistical Saga of Thrombolysis in Acute Ischemic Stroke
|
|
11
|
2217
|
December 21, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
2562
|
November 21, 2022
|
Is it appropriate to present confidence intervals (CIs) for the outcome in each treatment group in the context of clinical trials?
|
|
5
|
1437
|
November 2, 2022
|
Background to PFS endpoint
|
|
19
|
7161
|
October 6, 2022
|
Quality of remdesivir trials
|
|
54
|
18324
|
October 5, 2022
|
Cdisc in academia
|
|
1
|
1078
|
September 7, 2022
|
Patient-specific treatment effects in RCTs: why should one present them?
|
|
1
|
2286
|
August 13, 2022
|
Analyzing compositional outcome data
|
|
5
|
3473
|
July 28, 2022
|
Which to make as the primary analysis
|
|
1
|
2239
|
July 25, 2022
|
Non-inferiority and choice of scale (absolute vs relative)
|
|
4
|
1600
|
July 23, 2022
|
Evidence Based Decision Making and Meta-Analysis -- An Information Theoretic Critique
|
|
1
|
2398
|
June 10, 2022
|
Logistics of treatment effect estimation with interim analyses
|
|
1
|
1347
|
June 1, 2022
|
Should adverse effects be adjusted for multiple comparisons?
|
|
4
|
2846
|
May 24, 2022
|
Methodology: Benefit Risk Assessment when Risk and Benefit are only observed in different timing
|
|
5
|
1708
|
April 18, 2022
|
Covariate adjustment in non-inferiority trials
|
|
3
|
2720
|
April 14, 2022
|
RCT and "Mathematical Embellishment"
|
|
2
|
3235
|
April 5, 2022
|
Chi-Squared for relative risk
|
|
1
|
2109
|
March 27, 2022
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
9
|
3313
|
March 25, 2022
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
2682
|
March 6, 2022
|
Covariate imbalance in RCT
|
|
5
|
4194
|
February 23, 2022
|
Estimate treatment effect in study with a composite complication score as outcome
|
|
9
|
2572
|
February 18, 2022
|
Single cluster cluster randomized crossover (CRXO) design?
|
|
3
|
2011
|
February 17, 2022
|
Bernoulli trials vs completely randomized trials
|
|
0
|
2343
|
January 5, 2022
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
1867
|
December 28, 2021
|
Cost-effectiveness based interim analysis
|
|
2
|
2724
|
December 15, 2021
|
Interpretation of the REGEN-COV trial
|
|
22
|
10520
|
November 1, 2021
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
17672
|
October 8, 2021
|